News
Browse all news articles and resources.
Featured
3 articles
Insurance Gaps in Ketamine Care — And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Insurance Gaps in Ketamine Care — And One Fix
Most health insurers deny coverage for ketamine depression treatment in 2026. Here's what that means for patients and how access gaps are being bridged.
How Clinicians Choose TRD Treatments in 2026
New clinical guidance on treatment-resistant depression highlights how patient preference, speed of response, and functional outcomes shape ketamine treatment decisions.
Esketamine's Role in Treatment-Resistant Depression
A new clinical overview examines esketamine's place in TRD care, including patient selection, access barriers, and rapid-acting benefits for suicidal ideation.
Glutamate Pathway Treatments Reshape TRD Care in 2026
A 2026 review in Psychiatric Times highlights how esketamine and glutamate-targeting drugs are changing treatment-resistant depression care.
TRD Management: Why Remission Should Be the Goal
New clinical guidance on treatment-resistant depression urges full remission over symptom reduction — here's what it means for low-dose ketamine patients.
TRD Experts Push for Remission, Not Just Response
Psychiatrists are shifting TRD goals from symptom reduction to full remission. Here's what that means for ketamine patients and their treatment plans.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
Clinicians are pushing beyond symptom reduction in treatment-resistant depression, aiming for full remission. Here's what that means for ketamine patients.
Why Clinicians Are Pushing Harder on TRD Goals
New clinical thinking on treatment-resistant depression pushes toward true remission, not just symptom reduction. Here's what it means for ketamine patients.
Rethinking Treatment-Resistant Depression Care in 2026
New clinical perspectives on treatment-resistant depression push for true remission over symptom reduction. Here's what it means for ketamine patients.